22 Dec 2014 15:16
Lifeline Scientific, Inc. ("Lifeline" or "the Company")
Additional Listing
Lifeline Scientific, the medical technology company focused on the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation, announces the issue of 86,000 unrestricted shares under ISIN number US53223V1017 following the exercise of 32,000 share options and 54,000 shares issued in lieu of fees.
Application has been made to the London Stock Exchange for admission to AIM of 86,000 common shares of USD0.01 each. It is expected that admission will become effective in the Ordinary Shares on or around the 9 January 2015.
Subsequent to the admission above there will be 19,496,434 common shares in issue and each share has the right to one vote. Therefore for the purposes of the FCA Disclosure and Transparency Rules the total number of voting rights in the Company is 19,496,434.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the FCA's Disclosure and Transparency Rules.
22 December 2014
For further information:
Lifeline Scientific, Inc. Tel: +1 847-294-0300
David Kravitz, CEO
Lisa Kieres, CFO
Panmure Gordon (UK) Limited Tel: +44 20 7886 2500
Freddy Crossley (Corporate Finance)
Maisie R Atkinson (Corporate Broking)
FTI Consulting Tel: +44 20 7831 3113
Simon Conway / John Dineen
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. Today, it is widely recognised as the world's leading machine preservation device for kidneys. Employed by surgeons in over 135 leading transplant programmes in 23 countries worldwide, LifePorts have successfully preserved over 38,000 kidneys intended for clinical transplant. The product provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimise damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, LifePort records data on temperature, flow rate, vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. LifePort is the only system with clinical outcomes data produced from an independent, prospective, randomised, statistically powered, multi-centre clinical trial. Study results have been widely published in scientific journals, including the New England Journal of Medicine. Data indicates that patients receiving LifePort preserved kidneys experienced significant reduction in the incidence and duration of delayed graft function and increased graft survival at 1-year and 3-years post transplant. LifePort has also been recognised for its design and engineering. It has received prominent awards for design excellence from the medical device industry, has been selected for exhibition at the Smithsonian Cooper-Hewitt, National Design Museum and is part of the permanent Collection of The Museum of Modern Art (MoMA) in New York City.
About Lifeline Scientific, Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the FDA cleared, CE marked and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart, and lung are in late stage pre-clinical development.
see www.lifeline-scientific.com